Association between oral bisphosphonate use and dental implant failure among middle-aged women

[1]  N. Jewell,et al.  To GEE or Not to GEE: Comparing Population Average and Mixed Models for Estimating the Associations Between Neighborhood Risk Factors and Health , 2010, Epidemiology.

[2]  S. Koka,et al.  Survival of dental implants in post-menopausal bisphosphonate users. , 2010, Journal of prosthodontic research.

[3]  A. Goss,et al.  The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[4]  M. Sanz,et al.  What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. , 2009, Clinical oral implants research.

[5]  A. Khojasteh,et al.  Implant placement in patients with oral bisphosphonate therapy: a case series. , 2009, Clinical implant dentistry and related research.

[6]  M. Pogrel,et al.  The prognosis for dental implants placed in patients taking oral bisphosphonates. , 2009, Journal of the California Dental Association.

[7]  J. Lo,et al.  Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[8]  G. Hortobagyi,et al.  Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  S. Cremers,et al.  Inhibition of oral mucosal cell wound healing by bisphosphonates. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[10]  D. Burr,et al.  Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[11]  R. E. Bell,et al.  Oral bisphosphonates and dental implants: a retrospective study. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[12]  R. Kraut,et al.  Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[13]  R. Marx,et al.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[14]  P. Fugazzotto,et al.  Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. , 2007, Journal of periodontology.

[15]  M. Quirynen,et al.  Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. , 2007, Journal of clinical periodontology.

[16]  Gina Thornton-Evans,et al.  Trends in oral health status: United States, 1988-1994 and 1999-2004. , 2007, Vital and health statistics. Series 11, Data from the National Health Survey.

[17]  J. Kalmar,et al.  Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.

[18]  M. Jeffcoat.  Safety of oral bisphosphonates: controlled studies on alveolar bone. , 2006, The International journal of oral & maxillofacial implants.

[19]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Moy,et al.  Dental implant failure rates and associated risk factors. , 2005, The International journal of oral & maxillofacial implants.

[21]  J. Woodward,et al.  Agreement between self-reported information and medical claims data on diagnosed diabetes in Oregon's Medicaid population. , 2003, Journal of public health management and practice : JPHMP.

[22]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[23]  M. Pogrel,et al.  Osteonecrosis of the jaws associated with cancer chemotherapy. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  J. Li,et al.  Long‐Term Effect of Incadronate Disodium (YM‐175) on Fracture Healing of Femoral Shaft in Growing Rats , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  C. Poulter,et al.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.

[26]  S Winkler,et al.  Implant survival to 36 months as related to length and diameter. , 2000, Annals of periodontology.

[27]  J. Colwell,et al.  Dental endosseous implant assessments in a type 2 diabetic population: a prospective study. , 2000, The International journal of oral & maxillofacial implants.

[28]  N. Calonge,et al.  Validation of self-reported chronic conditions and health services in a managed care population. , 2000, American journal of preventive medicine.

[29]  G. Rodan,et al.  Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis , 1999, The Journal of Biological Chemistry.

[30]  B. Gertz,et al.  Pharmacokinetics of alendronate: an overview. , 1999, International journal of clinical practice. Supplement.

[31]  E. Pieterman,et al.  Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. , 1999, Biochemical and biophysical research communications.

[32]  L. Cooper,et al.  Generalizations regarding the process and phenomenon of osseointegration. Part II. In vitro studies. , 1998, The International journal of oral & maxillofacial implants.

[33]  R. Gillum,et al.  Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991. , 1997, Preventive medicine.

[34]  H. Fleisch,et al.  Bisphosphonates: mechanisms of action. , 1996, The Journal of clinical investigation.

[35]  N. Keenan,et al.  The validity of self-reported hypertension and correlates of hypertension awareness among blacks and whites within the stroke belt. , 1995, American journal of preventive medicine.

[36]  G. Rodan,et al.  Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. , 2000, Archives of biochemistry and biophysics.

[37]  Murray Jj,et al.  Trends in oral health , 1997 .